1. Home
  2. PCM vs CING Comparison

PCM vs CING Comparison

Compare PCM & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PCM Fund Inc.

PCM

PCM Fund Inc.

HOLD

Current Price

$5.27

Market Cap

66.8M

Sector

Finance

ML Signal

HOLD

CING

Cingulate Inc.

HOLD

Current Price

$5.26

Market Cap

64.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCM
CING
Founded
1993
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
66.8M
64.5M
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
PCM
CING
Price
$5.27
$5.26
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$34.50
AVG Volume (30 Days)
61.6K
132.7K
Earning Date
01-01-0001
05-08-2026
Dividend Yield
11.68%
N/A
EPS Growth
N/A
56.47
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.22
$3.16
52 Week High
$6.76
$11.89

Technical Indicators

Market Signals
Indicator
PCM
CING
Relative Strength Index (RSI) 25.78 52.86
Support Level $5.26 $5.08
Resistance Level $5.83 $5.54
Average True Range (ATR) 0.07 0.31
MACD -0.01 -0.04
Stochastic Oscillator 15.42 27.17

Price Performance

Historical Comparison
PCM
CING

About PCM PCM Fund Inc.

Pcm Fund Inc is a closed-end investment management company. Its investment objective is to seek current income as a primary focus and also capital appreciation. The Fund invests in agency-guaranteed mortgage-backed securities, private-label mortgage-backed securities, high-yield corporate debt securities, and commercial mortgage-backed securities.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: